Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL191346 | 0.80 | IDO1 (0.40) | IDO1 | |
| SCHEMBL29349590 | 0.80 | IDO1 (0.40) | IDO1 | |
| SCHEMBL4515094 | 0.70 | — | — | |
| SCHEMBL21541520 | 0.70 | IDO1 (0.36) | IDO1 | |
| SCHEMBL4488526 | 0.67 | — | — | |
| SCHEMBL4488760 | 0.67 | — | — | |
| SCHEMBL31571479 | 0.66 | ABCG2 (0.35) | IDO1 | |
| SCHEMBL29353113 | 0.66 | ABCG2 (0.35) | IDO1 | |
| SCHEMBL241482 | 0.66 | ABCG2 (0.35) | IDO1 | |
| SCHEMBL29427705 | 0.66 | HRH4 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481586-B2 | Pyrrolo[2,3-a] carbazoles and use thereof as PIM kinase inhibitors | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-07-09 | — | — | US | disclosed |
| US-8481586-B2 | Pyrrolo[2,3-a] carbazoles and use thereof as PIM kinase inhibitors | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-07-09 | — | — | US | disclosed |
| US-8481586-B2 | Pyrrolo[2,3-a] carbazoles and use thereof as PIM kinase inhibitors | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-07-09 | — | — | US | disclosed |
| US-8252814-B2 | Agents and crystals for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-28 | — | — | US | disclosed |
| EP-2326649-B1 | NOVEL PYRROLO[2,3-a]CARBAZOLES AND USE THEREOF AS PIM KINASE INHIBITORS | CENTRE NAT RECH SCIENT (FR) | 2012-03-28 | — | — | EP | disclosed |
| US-20110263669-A1 | Novel Pyrrolo [2,3-A] Carbazoles and Use Thereof as PIM Kinase Inhibitors | UNIVERSITE BLAISE PASCAL-CLERMONT-FERRAND II (FR) | 2011-10-27 | — | — | US | disclosed |
| US-20110263669-A1 | Novel Pyrrolo [2,3-A] Carbazoles and Use Thereof as PIM Kinase Inhibitors | UNIVERSITE BLAISE PASCAL-CLERMONT-FERRAND II (FR) | 2011-10-27 | — | — | US | disclosed |
| EP-2326649-A1 | NOVEL PYRROLO Ý2,3-A¨CARBAZOLES AND USE THEREOF AS PIM KINASE INHIBITORS | Centre National de la Recherche Scientifique (FR) | 2011-06-01 | — | — | EP | disclosed |
| WO-2010000978-A1 | NOVEL PYRROLO [2,3-A] CARBAZOLES AND USE THEREOF AS PIM KINASE INHIBITORS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-01-07 | — | — | WO | disclosed |
| US-20090264467-A1 | Agents and crystals for improving excretory potency of urinary bladder | ISHIHARA YUJI | 2009-10-22 | — | — | US | disclosed |
| US-20040053826-A1 | Uses of polypeptides | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
| US-20030207863-A1 | Preventives and remedies for central nervous system diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-11-06 | — | — | US | disclosed |
| EP-1331010-A1 | PREVENTIVES AND REMEDIES FOR CENTRAL NERVOUS SYSTEM DISEASES | Takeda Chemical Industries, Ltd. (JP) | 2003-07-30 | — | — | EP | disclosed |
| EP-1310490-A1 | GPR14 ANTAGONIST | Takeda Chemical Industries, Ltd. (JP) | 2003-05-14 | — | — | EP | disclosed |
| EP-1308513-A1 | USE OF POLYPEPTIDE | Takeda Chemical Industries, Ltd. (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-6534496-B1 | Prophylactic and/or therapeutic drug for obesity and obesity associated diseasestor diabetes with a reduced risk for central side effects and high universality in usage. Another object of the a lipolytic agent, or a prophylactic and/or | TAKEDA CHEMICAL INDUSTRIES, INC. (JP) | 2003-03-18 | — | — | US | disclosed |
| US-20020177593-A1 | Agents and crystals for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2002-11-28 | — | — | US | disclosed |
| EP-1118322-A1 | DRUGS FOR IMPROVING VESICAL EXCRETORY STRENGTH | Takeda Chemical Industries, Ltd. (JP) | 2001-07-25 | — | — | EP | disclosed |
| US-5620973-A | CHOLINESTERASE INHIBITOR; ALZHEIMER*S DISEASE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-04-15 | — | — | US | disclosed |
| EP-0655451-A1 | Tetracyclic condensed heterocyclic compounds for the treatment of senile dementia | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264467-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BCHE, PDE7A | IDO1 650/4885 |
| US-20020177593-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BPHL, BCHE | IDO1 583/4885 |
| US-20110263669-A1 | Novel Pyrrolo [2,3-A] Carbazoles and Use Thereof as PIM Kinase Inhibitors | PIM3, PIM1, PIM2 | IDO1 569/4885 |
| US-20040053826-A1 | Uses of polypeptides | NPSR1, SCTR, GRPR | IDO1 3709/4885 |
| US-20030207863-A1 | Preventives and remedies for central nervous system diseases | UTS2R, PRSS12, CTSA | IDO1 3137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.